Cosmo Pharmaceuticals N.V (C43) - Total Liabilities

Latest as of December 2025: €123.46 Million EUR ≈ $144.34 Million USD

Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) has total liabilities worth €123.46 Million EUR (≈ $144.34 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Cosmo Pharmaceuticals N.V - Total Liabilities Trend (2016–2025)

This chart illustrates how Cosmo Pharmaceuticals N.V's total liabilities have evolved over time, based on quarterly financial data. See Cosmo Pharmaceuticals N.V short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Cosmo Pharmaceuticals N.V Competitors by Total Liabilities

The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their total liabilities.

Company	Country	Total Liabilities
Boston Beer Company Inc NYSE:SAM	USA	$335.62 Million
Loma Negra Compania Industrial Argentina SA BA:LOMA	Argentina	AR$865.11 Billion
NV5 Global Inc NASDAQ:NVEE	USA	$440.77 Million
Shanghai QiFan Cable Co Ltd SHG:605222	China	CN¥10.05 Billion
ConnectOne Bancorp, Inc. NASDAQ:CNOB	USA	$12.62 Billion
Topscore Fashion SHG:603608	China	CN¥357.21 Million
BlackRock ESG Capital Allocation Trust NYSE:ECAT	USA	$182.33 Million
Europris ASA OL:EPR	Norway	Nkr7.91 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Cosmo Pharmaceuticals N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cosmo Pharmaceuticals N.V (C43) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.18	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cosmo Pharmaceuticals N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cosmo Pharmaceuticals N.V (2016–2025)

The table below shows the annual total liabilities of Cosmo Pharmaceuticals N.V from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€123.46 Million ≈ $144.34 Million	-12.86%
2024-12-31	€141.68 Million ≈ $165.64 Million	+15.73%
2023-12-31	€122.42 Million ≈ $143.12 Million	-58.61%
2022-12-31	€295.80 Million ≈ $345.83 Million	+1.00%
2021-12-31	€292.88 Million ≈ $342.41 Million	+49.40%
2020-12-31	€196.04 Million ≈ $229.19 Million	+2.41%
2019-12-31	€191.43 Million ≈ $223.80 Million	+5.86%
2018-12-31	€180.83 Million ≈ $211.41 Million	+549.14%
2017-12-31	€27.86 Million ≈ $32.57 Million	-0.21%
2016-12-31	€27.92 Million ≈ $32.64 Million	--

About Cosmo Pharmaceuticals N.V

F:C43 Germany Drug Manufacturers - General

Market Cap

$1.51 Billion

€1.29 Billion EUR

Market Cap Rank

#7347 Global

#1015 in Germany

Share Price

€75.50

Change (1 day)

+0.40%

52-Week Range

€57.50 - €139.00

All Time High

€153.25